Edition:
United States

Uniqure NV (QURE.OQ)

QURE.OQ on NASDAQ Stock Exchange Global Select Market

28.79USD
3:50pm EDT
Change (% chg)

$1.21 (+4.39%)
Prev Close
$27.58
Open
$27.64
Day's High
$29.36
Day's Low
$27.58
Volume
58,969
Avg. Vol
93,827
52-wk High
$43.23
52-wk Low
$9.47

Latest Key Developments (Source: Significant Developments)

UniQure ‍on Track To Begin Pivotal Study Of AMT-061 In Hemophilia B In Q3
Wednesday, 14 Mar 2018 07:00am EDT 

March 14 (Reuters) - Uniqure Nv ::UNIQURE ANNOUNCES 2017 FINANCIAL RESULTS AND RECENT COMPANY PROGRESS.UNIQURE NV - ‍ON TRACK TO BEGIN PIVOTAL STUDY OF AMT-061 IN HEMOPHILIA B IN Q3 2018​.UNIQURE NV - ‍EXPECTS IND SUBMISSION FOR AMT-130 IN HUNTINGTON'S DISEASE IN SECOND HALF OF 2018​.UNIQURE NV - ‍$159 MILLION OF CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017​.  Full Article

Uniqure Says As Of Dec 31 Co Had $159 Mln In Cash & Cash Equivalents
Monday, 8 Jan 2018 07:00am EST 

Jan 8 (Reuters) - Uniqure Nv ::UNIQURE PROVIDES YEAR-END 2017 CORPORATE UPDATE AND OUTLINES NEAR-TERM OBJECTIVES TO FURTHER DRIVE SHAREHOLDER VALUE.UNIQURE - AS OF DEC 31, 2017, CO HAD ABOUT $159 MILLION IN CASH & CASH EQUIVALENTS; EXPECTS CASH ON HAND SUFFICIENT TO FUND OPERATIONS INTO 2020.UNIQURE NV - INTENDS TO INITIATE GLOBAL, PIVOTAL PROGRAM FOR AMT-061 IN HEMOPHILIA B DURING Q3 2018.UNIQURE NV - AMENDMENT TO EXISTING INVESTIGATIONAL NEW DRUG (IND) APPLICATION EXPECTED FOR AMT-061 TO BE SUBMITTED TO FDA IN Q1 2018.  Full Article

UniQure Announces Updated, Long-Term Clinical Data From Ongoing Phase I/II Trial Of AMT-060 In Patients With Severe Hemophilia B
Monday, 11 Dec 2017 07:00am EST 

Dec 11 (Reuters) - Uniqure Nv ::UNIQURE ANNOUNCES UPDATED, LONG-TERM CLINICAL DATA FROM ONGOING PHASE I/II TRIAL OF AMT-060 IN PATIENTS WITH SEVERE HEMOPHILIA B.UNIQURE -AAV5-BASED AMT-060 REMAINS SAFE,WELL-TOLERATED WITH UPTO 2 YEARS OF FOLLOW-UP,WITH NO NEW SERIOUS ADVERSE EVENTS,NO DEVELOPMENT OF INHIBITORS.  Full Article

Uniqure Q3 loss per share $0.40
Wednesday, 1 Nov 2017 07:00am EDT 

Nov 1 (Reuters) - Uniqure Nv ::Uniqure announces third quarter 2017 financial results and recent company progress.Q3 loss per share $0.40.Q3 revenue $2.3 million versus $7.2 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

UniQure reports Q3 loss $0.40/shr
Wednesday, 1 Nov 2017 07:00am EDT 

Nov 1 (Reuters) - UniQure Nv :UniQure announces third quarter 2017 financial results and recent company progress.Q3 loss per share $0.40.Q3 revenue $2.3 million versus $7.2 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

Uniqure NV says ‍priced its underwritten public offering of 5 mln shares at $18.25 per share​
Tuesday, 24 Oct 2017 09:13pm EDT 

Oct 24 (Reuters) - Uniqure NV -:Uniqure announces pricing of its public offering.Uniqure NV says ‍announced pricing of its underwritten public offering of 5 million of its ordinary shares at a public offering price of $18.25 per share​.  Full Article

Uniqure announces proposed public offering
Monday, 23 Oct 2017 04:06pm EDT 

Oct 23 (Reuters) - Uniqure NV ::Uniqure announces proposed public offering.Uniqure NV - ‍ commenced an underwritten public offering of 5 million of its ordinary shares.  Full Article

uniQure acquires patent family providing broad protection of hyperactive padua variant of factor IX
Thursday, 19 Oct 2017 07:05am EDT 

Oct 19 (Reuters) - uniQure Nv :uniQure strengthens intellectual property portfolio with acquisition of patent family providing broad protection of the hyperactive padua variant of factor ix (FIX-padua).  Full Article

Uniqure announces AMT-061 to enter pivotal study in 2018
Thursday, 19 Oct 2017 07:00am EDT 

Oct 19 (Reuters) - Uniqure Nv :Uniqure announces Hemophilia B gene therapy program to enter pivotal study with FIX-Padua variant in 2018.Uniqure NV - ‍plans to initiate pivotal study with enhanced AMT-061 in 2018​.Uniqure nv - ‍acquired patent family that covers FIX-Padua variant and its use in gene therapy for treatment of Coagulopathies, including Hemophilia B​.Uniqure - ‍FDA agreed AMT-061 will be included under existing breakthrough therapy designation and IND for AMT-060​.Uniqure NV - ‍EMA also has agreed that AMT-061 will be included under current prime designation​.  Full Article

Uniqure announces FDA orphan drug designation for AMT-130 in huntington’s disease
Friday, 6 Oct 2017 07:00am EDT 

Oct 6 (Reuters) - Uniqure NV : :Uniqure announces FDA orphan drug designation for AMT-130 in huntington’s disease.  Full Article